Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability

Codis agreed to acquire Catalent’s Nottingham, UK facility, expected to close in Q3 2026, adding oral solid dose (OSD) development and small-scale manufacturing capabilities. The deal positions Codis as a leading integrated end-to-end spray-drying partner in Europe (development through clinical supply and commercial intermediates to final oral dose forms). It complements the Haverhill, UK commercial PSD-4 spray dryer investment (validation scheduled for 2027), supporting Codis’ ability to de-risk formulation-to-commercial scale transfer.

Analysis

This is more of a moat-builder than an immediate P&L event. The strategic value is that it reduces the failure rate between development and GMP scale-up, which should improve win rates on late-stage programs where customers pay for de-risking more than raw capacity. That usually shows up first as higher quote conversion and stickier relationships, then only later as margin leverage once the new integrated workflow is filled.

The second-order effect is competitive: standalone formulation shops and smaller OSD CDMOs lose differentiation if a full development-to-commercial path can be sold inside one quality system. That can pressure pricing in spray drying-adjacent services, but it should also expand the total addressable market for poorly soluble small molecules because sponsors are more willing to advance marginal assets when tech transfer risk is lower. The key question is whether Codis can keep utilization high enough to justify the added fixed-cost base.

Near term, the market may over-assign credit to the announcement because the revenue payoff is likely 12-24 months out, while integration expense and capex come first. The main falsifier is weak booking momentum or evidence that the acquired site was underutilized for structural reasons rather than capacity constraints. Watch for customer announcements, backlog growth, and any margin commentary after closing; without those, this is a capability story, not an earnings inflection.

Key Decisions for Investors

• Small tactical long EVRRF on pullbacks over the next 1-4 weeks, but size modestly; thesis is multiple support from a stronger platform story rather than near-term EPS upside.
• If EVRRF has been running into the announcement, fade strength unless management later quantifies booked demand; the most likely risk/reward is better on a retrace than on chasing the open.
• Use a 3-6 month catalyst watch on EVRRF: confirm whether integrated-site wins and backlog growth translate into utilization. If not, expect the market to discount the capex-heavy story.
• Relative-value idea: prefer EVRRF over lower-differentiation CDMO names with no integrated spray-dry/OSD footprint; the winner should be the platform with the lowest tech-transfer friction.